Chen Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chen Zhang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Guoqing Ding
Department of Urology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
14 shared publications - Jie Zhang
Department of Urology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
14 shared publications - Ruichen Zang
Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China
14 shared publications - Xudong Wang
Sir Run Run Shaw Hospital, Hangzhou, China
13 shared publications - Yanlan Yu
Department of Urology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
13 shared publications - Yicheng Chen
Department of Urology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
13 shared publications
Latest Publications
- 2 July 2026
- Published by Elsevier in Trends in Cancer
- Vol. 12 (10) , 950-961
Itaconate in cancer immunity: Evidence, ambiguities, and translational barriers
- 2 July 2026
- Published by Elsevier in Trends in Cancer
- Vol. 12 (10) , 950-961
Itaconate in cancer immunity: Evidence, ambiguities, and translational barriers
- Open Access
- 18 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9, 1316
Extracellular metabolites and NK cell antitumor function: mechanisms and therapeutic strategies
Natural killer (NK) cells are innate cytotoxic lymphocytes capable of eliminating malignant cells independent of prior antigen sensitization, thereby constituting a critical first-line defense in tumor immunosurveillance. Within the tumor microenvironment (TME), metabolic dysregulation profoundly impairs NK cell effector function, and accumulating studies have investigated the regulatory effects of extracellular metabolites on NK cells. This review systematically delineates the direct mechanistic interplay between extracellular metabolites and NK cell antitumor immunity, with particular emphasis on their roles as structural components, bioenergetic substrates, metabolic reprogramming inducers, modification donors, gene transcription regulators, stress response mediators, intracellular pH modulators, and ligands engaging cognate receptors to initiate downstream signaling cascades. Furthermore, we discuss the therapeutic strategies targeting metabolites to potentiate NK cell functionality, encompassing modulation of metabolite availability within the TME and exploitation of metabolite-sensitive signaling axes. In addition, combination of metabolic interventions with other modalities, such as adoptive NK cell transfer and anti-programmed cell death protein 1/programmed death-ligand 1 therapy, is also evaluated for prospective applications. This review provides a conceptual framework for understanding the metabolic regulation of NK cells, highlighting emerging directions for advancing NK-cell-centered cancer immunotherapy through metabolic modulation.
- 18 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9, 1316
Open AccessExtracellular metabolites and NK cell antitumor function: mechanisms and therapeutic strategies
Natural killer (NK) cells are innate cytotoxic lymphocytes capable of eliminating malignant cells independent of prior antigen sensitization, thereby constituting a critical first-line defense in tumor immunosurveillance. Within the tumor microenvironment (TME), metabolic dysregulation profoundly impairs NK cell effector function, and accumulating studies have investigated the regulatory effects of extracellular metabolites on NK cells. This review systematically delineates the direct mechanistic interplay between extracellular metabolites and NK cell antitumor immunity, with particular emphasis on their roles as structural components, bioenergetic substrates, metabolic reprogramming inducers, modification donors, gene transcription regulators, stress response mediators, intracellular pH modulators, and ligands engaging cognate receptors to initiate downstream signaling cascades. Furthermore, we discuss the therapeutic strategies targeting metabolites to potentiate NK cell functionality, encompassing modulation of metabolite availability within the TME and exploitation of metabolite-sensitive signaling axes. In addition, combination of metabolic interventions with other modalities, such as adoptive NK cell transfer and anti-programmed cell death protein 1/programmed death-ligand 1 therapy, is also evaluated for prospective applications. This review provides a conceptual framework for understanding the metabolic regulation of NK cells, highlighting emerging directions for advancing NK-cell-centered cancer immunotherapy through metabolic modulation.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
Table S4 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
Table S4 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
Exosomal PD-1 activation of JAK-STAT3 in myeloid progenitor cells
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
Exosomal PD-1 activation of JAK-STAT3 in myeloid progenitor cells
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
USP7 regulates PD-1 stabilization
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
USP7 regulates PD-1 stabilization
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
PD-1 promotes tumor progression
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
PD-1 promotes tumor progression
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
Table S3 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
Table S3 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
Endogenous PD-1 promotes neutrophil-related chemokine production
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
Endogenous PD-1 promotes neutrophil-related chemokine production
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
Table S1 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
Table S1 from Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion